Pulmonary Hypertension

Depression, anxiety and psychological distress in patients with pulmonary hypertension: a mixed-methods study - DocWire News Depression, anxiety and psychological distress in patients with pulmonary hypertension: a mixed-methods study - DocWire News Posted: 29 Apr 2021 11:00 PM PDT This article was originally published here BMJ Open Respir Res. 2021 Apr;8(1):e000876. doi: 10.1136/bmjresp-2021-000876. ABSTRACT INTRODUCTION: Pulmonary hypertension (PH) is a chronic and progressive disease. While prognoses have improved, PH patients still experience side effects and activity restrictions. Accordingly, the key questions asked by this study are 'How many PH patients have depression/anxiety symptoms?' and 'Is there a difference in the symptoms and distress factors between pulmonary arterial hypertension (PAH) and chronic thromboembolic PH (CTEPH) patients, and how are they experiencing distress?' METHODS: A mixed-methods ...

Outcomes Poorer for PH-COPD Than Idiopathic PAH, Registry Data Show - Pulmonary Hypertension News Outcomes Poorer for PH-COPD Than Idiopathic PAH, Registry Data Show - Pulmonary Hypertension News Posted: 09 Apr 2021 12:00 AM PDT Patients whose pulmonary hypertension is associated with chronic obstructive pulmonary disease ( PH-COPD ) have a worse clinical status and a poorer outcome than those with idiopathic pulmonary arterial hypertension ( IPAH ), a study based on real-world data from the COMPERA registry reports. Although PH is typically mild to moderate in COPD , some patients develop severe PH. According to the study, targeted PAH therapies might improve the clinical status of this particular group of patients. The study, " Pulmonary hypertension in patients with chronic obstructive lung disease: results from COMPERA ," was published in the journal CHEST . COMPERA and COMPERA-KI...

United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease - PRNewswire United Therapeutics Announces FDA Approval and Launch of Tyvaso® for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease - PRNewswire Posted: 01 Apr 2021 12:00 AM PDT SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C. , April 1, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR ) today announced that the U.S. Food and Drug Administration (FDA) has approved Tyvaso ® (treprostinil) Inhalation Solution for the treatment of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. This is the second FDA-approved indication for Tyvaso, which was first approved in July 2009 for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exerc...

Pulmonary Arterial Hypertension: Updates in Epidemiology and Evaluation of Patients - AJMC.com Managed Markets Network Pulmonary Arterial Hypertension: Updates in Epidemiology and Evaluation of Patients - AJMC.com Managed Markets Network Posted: 11 Mar 2021 12:00 AM PST Am J Manag Care . 2021;27(3):S35-S41. https://doi.org/10.37765/ajmc.2021.88609 Introduction Pulmonary hypertension (PH) describes a group of severe pulmonary vascular disorders characterized by elevated mean pulmonary arterial pressure (mPAP) at rest. 1 The World Symposium on Pulmonary Hypertension (WSPH) categorizes pulmonary hypertension into 5 groups (Table 1). 2 Pulmonary arterial hypertension (PAH), which corresponds to group 1 PH, and a focus of this article, is a complex and devastating disease that causes progressive vasoconstriction and vascular remodeling of the distal pulmonary arteries. 3 Currently, there is no cure, and the majority of patients with PAH go o...